378 related articles for article (PubMed ID: 11571636)
1. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
[TBL] [Abstract][Full Text] [Related]
3. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.
July LV; Beraldi E; So A; Fazli L; Evans K; English JC; Gleave ME
Mol Cancer Ther; 2004 Mar; 3(3):223-32. PubMed ID: 15026542
[TBL] [Abstract][Full Text] [Related]
4. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.
Zellweger T; Chi K; Miyake H; Adomat H; Kiyama S; Skov K; Gleave ME
Clin Cancer Res; 2002 Oct; 8(10):3276-84. PubMed ID: 12374699
[TBL] [Abstract][Full Text] [Related]
5. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
[TBL] [Abstract][Full Text] [Related]
6. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
7. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
[TBL] [Abstract][Full Text] [Related]
8. Suppression of clusterin expression enhanced cisplatin-induced cytotoxicity on renal cell carcinoma cells.
Lee CH; Jin RJ; Kwak C; Jeong H; Park MS; Lee NK; Lee SE
Urology; 2002 Sep; 60(3):516-20. PubMed ID: 12350509
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
Springate CM; Jackson JK; Gleave ME; Burt HM
Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591
[TBL] [Abstract][Full Text] [Related]
11. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
[TBL] [Abstract][Full Text] [Related]
13. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
Miyake H; Hara I; Kamidono S; Gleave ME
Clin Cancer Res; 2001 Dec; 7(12):4245-52. PubMed ID: 11751526
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
[TBL] [Abstract][Full Text] [Related]
15. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
Gleave M; Miyake H
World J Urol; 2005 Feb; 23(1):38-46. PubMed ID: 15770517
[TBL] [Abstract][Full Text] [Related]
16. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.
Miyake H; Hara I; Kamidono S; Gleave ME; Eto H
Oncol Rep; 2003; 10(2):469-73. PubMed ID: 12579291
[TBL] [Abstract][Full Text] [Related]
17. Clusterin promotes growth and invasion of clear cell renal carcinoma cell by upregulation of S100A4 expression.
Liu Y; Men C; Xu Y; Zhao K; Luo L; Dong D; Yu Q
Cancer Biomark; 2018; 21(4):915-923. PubMed ID: 29400663
[TBL] [Abstract][Full Text] [Related]
18. Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo.
Hara I; Miyake H; Gleave ME; Kamidono S
Jpn J Cancer Res; 2001 Nov; 92(11):1220-4. PubMed ID: 11714447
[TBL] [Abstract][Full Text] [Related]
19. Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.
Nishikawa M; Miyake H; Gleave M; Fujisawa M
Target Oncol; 2017 Feb; 12(1):69-79. PubMed ID: 27526062
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.
So A; Sinnemann S; Huntsman D; Fazli L; Gleave M
Mol Cancer Ther; 2005 Dec; 4(12):1837-49. PubMed ID: 16373699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
